Salivary cortisol response to psychosocial stress in patients with first-episode psychosis

Aim To analyze the difference in the salivary cortisol response to psychosocial stress between the patients with the first episode of psychosis (FEP) and the control group.

Methods We performed a cross-sectional analysis of the baseline measurements of a prospective cohort study conducted from 2015 to 2018 at two Croatian psychiatric hospitals. The study consecutively enrolled 53 patients diagnosed with FEP and 63 healthy controls. The primary outcome was the difference in the changes of salivary cortisol concentration during the stress test. The secondary outcome was the difference in the baseline levels of salivary cortisol between patients with FEP and controls. The tertiary outcome were the correlations of salivary cortisol levels with the results of the Positive and Negative Syndrome Scale for Schizophrenia, Rosenberg Self-Esteem Scale, and the International Personality Item Pool.

Results Patients with FEP had significantly higher baseline salivary cortisol than controls, but their salivary cortisol increased significantly less during the stress test.

Conclusion Patients with FEP respond differently to stressful stimuli than controls, as shown by the increased baseline salivary cortisol and blunted cortisol response, possibly indicating a greater vulnerability to psychosocial stress.
Schizophrenia is one of the most complex psychiatric disorders (1), and in most cases, a long-term condition characterized by alternating periods of acute psychosis and remission. The first episode of psychosis (FEP) is usually preceded by a prodromal phase with non-specific symptoms, followed by psychotic symptoms pertaining to five dimensions; positive, negative, affective, cognitive, and psychomotor. While the pathogenesis is largely unknown, different streams of research consistently show that schizophrenia results from a complex gene-environment interaction (2), in line with the stress-diathesis model of schizophrenia etiology (3). According to this model, genetic and environmental factors lead to vulnerability to schizophrenia (2), and schizophrenia occurs when the vulnerable person experiences "enough" stress (4). For the majority of people, significant distress is associated with major stressors, eg, death in the family, serious illness, or separation (5). However, in persons prone to psychosis, significant distress is caused even by minor stressors, also known as daily hassles (6).

Response to stress involves the activation of the hypothalamic-pituitary-adrenal axis (HPA); the hypothalamus secretes corticotropin-releasing factor (CRF), which stimulates the secretion of adrenocorticotropic hormone (ACTH) from the front pituitary gland. ACTH then stimulates the release of cortisol from the adrenal gland, causing the cascading effect of several bodily systems (immune, neuroendocrine, inflammatory response to the organism, etc) (7). In the central nervous system, increased cortisol levels can lead to the sensitization of dopaminergic response to stress, which can lead to an excessive dopamine release and psychotic symptoms (6). Indeed, various indicators of altered stress response have been confirmed in the population at risk for psychosis compared with healthy population (8,9).

While it has been suggested that persons with schizophrenia show a blunted cortisol response following experimentally induced psychosocial stress (10,11), these findings should be further elucidated considering the heterogeneous research results. Some of these discrepancies may arise from the heterogeneity of the samples and different confounding factors but also from different stress response across illness types and stages (12).

Generally, persons with FEP show higher basal cortisol values than the healthy population (8,13,14), a finding that possibly indicates their increased basic HPA hyperactivity, which contributes to their higher vulnerability to stressors. HPA axis hyperactivity indicated by elevated basal cortisol levels in individuals with psychosis is expected to also produce a higher acute elevation of cortisol concentrations in response to acute stressful situation (11). However, studies on FEP are not uniform in their findings (5-7). A small study with eleven medication-naïve patients found an attenuated response of cortisol to psychosocial stress (15). Furthermore, Pruessner et al (16) reported significantly lower cortisol levels and systolic blood pressure during the psychosocial stress task in an ultra-high-risk group compared with controls; the lower cortisol levels were associated with higher self-rated stress in the past year. The authors suggested that in these patients attenuated stress response reflects the vulnerability to stressors. A recent study among patients with FEP obtained contrary results, ie, lower salivary cortisol levels at baseline but no difference in the cortisol response during psychosocial stress challenge test compared with healthy controls (17). Another study found no differences in baseline salivary cortisol levels between patients with FEP and controls, but a blunted cortisol response to stressors in FEP, both on and off medication, compared with controls (18). Finally, individuals with schizophrenia have shown lower cortisol levels both in anticipation and after exposure to social stress compared with controls, even though there were no differences in cortisol production rate (19).

Of note, people with posttraumatic stress syndrome (20) and those with high anxiety traits (21) showed higher salivary baseline cortisol, but a blunted response to psychosocial stress compared with healthy controls (22), which suggests a deficient acute neuroendocrine stress response.

Thus, the aim of our study was to assess the difference in the salivary cortisol response to the psychosocial stress between the patients with FEP and healthy controls. We enrolled only patients with FEP who were homogeneous in age, duration of illness, phase of illness, and with minimal exposure to medication to limit some of the major confounding factors from other studies. We hypothesized that patients with FEP showed higher baseline salivary cortisol levels, which indicates increased basic HPA hyperactivity, and a lower cortisol increase in response to psychosocial stressor compared with HC, as an indicator of an aberrant response to psychosocial stress. Our exploratory aim was to analyze the correlation of other clinical factors, including psychopathology, personality traits, and stressful life events with salivary cortisol levels.
PATIENTS AND METHODS

Study design

We performed the cross-sectional analysis on a subset of patients enrolled to a larger prospective cohort study described elsewhere (1). The larger prospective cohort study lasted from October 1, 2015 to February 31, 2018, and this analysis was performed on the patients enrolled from March 1, 2015 to December 31, 2017 only at the Department of Psychiatry, Zagreb University Hospital Centre, and Dr Ivan Barbot Neuropsychiatric Hospital, and not in other prospective cohort study centers. The study protocol was approved by the Ethics Committee of Zagreb University Hospital Centre and the Ethics Committee of Dr Ivan Barbot Neuropsychiatric Hospital. Participants signed the informed consent form. Their anonymity was protected by keeping the informed consents forms separately from the data collection instruments. We performed the study in accordance with World Medical Association Declaration of Helsinki of 1975, as revised in 2013 (23).

Study population

The target population were patients of both sexes, 18 to 45 years old, diagnosed with FEP (codes F20, F23, F29) according to the International Classification of Diseases – 10th Revision (24). We enrolled only patients with FEP who were homogenous in age, duration of illness, phase of illness, and with minimal exposure to medication to limit some of the major confounding factors from other studies. The diagnosis was made by two experienced psychiatrists, MRK and MCR. The exclusion criteria for patients were childhood mental disorders that may present with psychosis (eg, autism), neurological disorders, moderate or severe mental retardation, and addiction to alcohol and psychoactive substances in comorbidity, pregnancy, lactation, and the use of drugs that may cause psychotic reactions for both patients and healthy controls.

All patients received standard care provided in the mentioned hospitals (treatment as usual), with medication indicated by the treating psychiatrists. The core of the hospital treatment was pharmacotherapy, based on available second- and first-generation antipsychotics (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, haloperidol, fluphenazine) applied orally or as long acting injectables (LAIs, for aripiprazole, olanzapine, paliperidone, risperidone, and first-generation antipsychotics). Sedatives, mood stabilizers, and antidepressants were allowed according to the clinician’s indication (Table 1). After reaching the subacute phase of psychosis (usually in the first few weeks of medication treatment), patients were discharged from hospital, and their medication at discharge was recorded. The assessments were performed once the patients’ clinical condition allowed it (for the majority in the sixth-eighth week of treatment).

The control group included people of both sexes, 18 to 45 years old, with a negative history of psychotic disorders and other previously stated exclusion criteria. They were selected from a convenience sample of hospital staff and medical students. All included participants were interviewed by the study researchers upon study inclusion. The control group was recruited at the same time as the FEP cohort.

Assessment of participants

All participants completed the Rosenberg Self-Esteem Scale (SES) (25) and the International Personality Item

| TABLE 1. Characteristics of participants with first-episode psychosis (FEP) and controls. Data are shown as count and percentage unless otherwise indicated* |
|----------------------------------|------------------|------------------|
|                                  | **FEP group**    | **Control group** |
|                                  | *(n = 53)*        | *(n = 63)*        |
| Female sex                       | 21 (39.6)        | 34 (54.0)        |
| Age, median (IQR)                | 25 (23-29)       | 22 (21-25)       |
| University education             | 10 (18.9)        | 18 (28.6)        |
| Being employed                   | 13 (24.5)        | 19 (30.2)        |
| Smoking tobacco                  | 22 (41.5)        | 11 (17.5)        |
| Antipsychotics                   |                 |                  |
| monotherapy                      | 33 (62.3)        |                  |
| combination therapy              | 20 (37.7)        |                  |
| Generation†                      |                  |                  |
| first                            | 15 (28.3)        |                  |
| second                           | 47 (88.7)        |                  |
| Way of application               |                 |                  |
| oral                             | 48 (90.6)        |                  |
| LAI                              | 7 (13.2)         |                  |
| Benzodiazepines                  | 23 (43.4)        |                  |
| Mood stabilizers                 | 11 (20.8)        |                  |
| Antidepressants                  | 10 (18.9)        |                  |
| Anticholinergics                 | 9 (17.0)         |                  |
| Symptoms severity, mean (SD)     |                 |                  |
| PANSS total score                | 96 (22.4)        |                  |
| positive symptoms                | 23 (8.5)         |                  |
| negative symptoms                | 23 (7.0)         |                  |
| general symptoms                 | 50 (9.9)         |                  |

*Abbreviations: FEP – first episode psychosis; LAI – long-acting injectable; IQR – interquartile range, PANSS – The Positive and Negative Syndrome Scale for Schizophrenia.
†The sum exceeds 100% due to the combination therapies.
Pool (IPIP) (26). Psychopathology assessment with the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scale (27) was conducted by experienced raters MRK and MCR.

The protocol for the stress paradigm

We used a modification of the Montreal Imaging Stress Task (28) and the Trier’s Social Stress Test (TSST) (29,30). The combination of public speaking and cognitive task robustly increases cortisol (29), probably as a result of their association with social evaluative threat and uncontrollability, two important characteristics of psychological stressors (31). All participants refrained from eating, drinking, and smoking one hour before the test session. Saliva samples were collected at five time points during the test to assess salivary cortisol levels, as described in our published research protocol (1). Testing sessions took place from 13:00 to 16:00, to minimize the impact of diurnal rhythm on the cortisol response. Participants were informed about the nature of the task after baseline saliva samples had been collected. Saliva was collected using pre-labeled Salivettes® (Sarstedt, Nümbrecht, Germany) on the day of psychosocial stress testing.

Salivary cortisol was measured at the Department of Laboratory Diagnostics Zagreb University Hospital Centre (1) with fully automated analyzer Roche Cobas c6000, using electrochemiluminescence immunoaassay (32). The saliva samples were collected according to a previously described protocol (33).

Statistical analysis

The needed sample size was estimated before the start of data collection based on a pilot study performed with 14 FEP patients and 17 participants with no psychotic symptoms. These participants were not included in the main study sample. The final sample of 54 in each group was needed to detect a small effect size of partial eta squared coefficient ($\eta^2$) = 0.03 at two-tail $P < 0.05$ with 0.80 power when analyzing the interaction of time during the stress test and the study group by a mixed, between-within subjects analysis of covariance. The analysis was adjusted for the preplanned covariates with possible confounding effects. We controlled possible confounding effects of age, sex, education, and work status by multivariable analysis. We analyzed the secondary outcome: differences in the baseline cortisol levels between FEP and controls using the analysis of covariance with adjustment for age, sex, education, and employment.

The normality of residuals was assessed by inspecting the histograms and Q-Q plots. We calculated $\eta^2$ and Cohen’s $d$ as the standardized effect sizes. To control the effect of multiple testing in secondary and tertiary outcomes, we used the Benjamini-Hochberg method with the false-discovery rate (FDR) set at ≤10% but considering all, the primary and tertiary outcome testing as well (study-wise correction). To assess the tertiary, explorative outcome, correlations of the cortisol levels and the results of the IPIP, SES, and PANSS in patients with FEP, we used the Spearman’s correlation coefficient and a study-wise correction for multiple testing. The level of statistical significance was set at $P < 0.05$, always in two-tails tests, and all confidence intervals at 95%. The data analysis was performed with the R Core Team (2014), a language and environment for statistical computing (34).

RESULTS

We enrolled 53 patients with FEP and 63 controls. FEP patients were more often men, somewhat older, less educated, and more often unemployed than controls (Table 1). Baseline cortisol measured before the stress test was higher in FEP than in controls (means [SD] for FEP and HC were 13.3 [6.49] nmol/L and 10.0 [4.21] nmol/L, respectively). This difference of 33% relative to the concentration in the control group was significant both in the bivariable analysis ($F (1.114) = 11.3; P = 0.001$;
η² = 0.09; d = 0.63; FDR<10%) and after adjustment for age, sex, education, and employment (F(1,109) = 9.4; P = 0.003; η² = 0.08; d = 0.59; FDR<10%).

The change of cortisol level between the lowest value measured at the third minute after the participant preparation and the highest value measured after the stress test at the 13th minute was significantly smaller in FEP patients than in controls (Table 2, Figure 1). In the FEP group, cortisol increased for a mean of 19% (94%; CI 12%-27%), while in the control group it increased for a mean of 55% (95%; CI 37%-79%). The interaction of measurement and the study group was significant both in the bivariable analysis (F (1.114) = 6.0; P = 0.016; η² = 0.05; d = 0.46) and after the adjustment for age, sex, education, and employment (F (1.110) = 4.7; P = 0.032; η² = 0.04; d = 0.41). The lowering of cortisol during the 30 minutes after the stress test completion was not significantly different between the FEP and control group after the Benjamini-Hochberg correction with FDR<10% (Table 3, Figure 1).

In patients, only baseline cortisol levels significantly positively correlated with negative and positive PANSS subscales, and emotional stability IPIP subscale, with one exception. However, in controls salivary cortisol levels positively correlated with emotional stability IPIP subscale, 

### TABLE 2. Change in salivary cortisol concentration (nmol/L) from the preparation (3rd min.) to after the test (13th min.). Data are presented as mean (standard deviation) in unadjusted and mean (95% confidence interval) in adjusted analysis*

|                  | After the preparation (3rd min.) | After the test (13th min.) | Δ     | CI₉₅% | Δ%   | CIₓₓₓₓₓ, % | η²  | d     | p   |
|------------------|----------------------------------|---------------------------|-------|-------|------|-----------|------|-------|-----|
| **Unadjusted**   |                                  |                           |       |       |      |           |      |       |     |
| FEP              | 11.8 (5.53)                      | 13.7 (6.66)               | 1.9   | 1.0-2.8 | 19   | 12-27     | 0.05 | 0.016 |     |
| Control group    | 9.3 (4.16)                       | 12.9 (5.97)               | 3.6   | 2.7-4.6 | 55   | 37-79     | 0.46 |       |     |
| **Adjusted†**   |                                  |                           |       |       |      |           |      |       |     |
| FEP              | 11.8 (10.4-13.1)                 | 13.7 (11.9-15.4)          | 1.9   | 0.8-3.0 | 19   | 0-39      | 0.04 | 0.032 |     |
| Control group    | 9.3 (8.1-10.5)                   | 12.9 (11.3-14.5)          | 3.6   | 2.6-4.6 | 55   | 38-73     | 0.41 |       |     |

*Abbreviations: FEP – first episode psychosis; Δ – mean of absolute differences between the first and second measurement; Δ% – mean of relative differences calculated as the absolute difference divided by the baseline value; η² – standardized effect size partial Eta squared; d – standardized effect size Cohen’s d; p – statistical significance of the interaction between time of measurement and the study group calculated using mixed between-within analysis of variance in unadjusted and analysis of covariance in adjusted analysis.

†Means were adjusted for age, sex, education, and employment status.
and negatively with SES and intellect/imagination IPIP subscale, in almost all measurements (Table 4).

**DISCUSSION**

In line with our hypothesis, we found that the patients with FEP had higher baseline levels of salivary cortisol and a blunted cortisol increase in response to psychosocial stressor compared with controls, but the groups did not differ in cortisol decrease after the peak activity. This is compatible with the results by Pruessner et al (16), who found significantly lower cortisol levels during the Trier Social Stress Test among persons at ultra-high risk for psychosis compared with controls. It is also compatible with a recent

**TABLE 3.** Change in salivary cortisol concentration (nmol/L) from 13 to 30 min. after the test. Data are presented as mean (standard deviation) in unadjusted and mean (95% confidence interval) in adjusted analysis*

|                      | After the test (13th min.) | 30th min. after the test | Δ       | CI 95%  | Δ%       | CI 95% % | η²d | p       | B-H |
|----------------------|---------------------------|--------------------------|---------|---------|----------|----------|-----|---------|-----|
| **Unadjusted**       |                           |                          |         |         |          |          |     |         |      |
| FEP                  | 13.7 (6.66)               | 12.4 (5.90)              | -1.2    | -2.3 to-0.33 | -6       | -13-0    | 0.02 | 0.108   |      |
| Control group        | 12.9 (5.97)               | 12.9 (6.43)              | -0.3    | -1.0-1.1 | 3        | -5-12    | 0.29 |         |      |
| **Adjusted†**        |                           |                          |         |         |          |          |     |         |      |
| FEP                  | 13.7 (11.9-15.4)          | 12.2 (10.5-13.9)         | -1.5    | -2.6 to-0.4 | -9       | -18-0    | 0.04 | 0.034   | n.s.|
| Control group        | 12.9 (11.3-14.5)          | 13.1 (11.6-14.7)         | 0.2     | -0.8-1.2 | 5        | 0-13     | 0.41 |         |      |

*Abbreviations: FEP – first episode psychosis; Δ – mean of absolute differences between the first and second measurement; Δ% – mean of relative differences calculated as the absolute difference divided by the baseline value; η²d – standardized effect size partial Eta squared; d – standardized effect size Cohen’s d; p – statistical significance of the interaction between time of measurement and the study group calculated using mixed between-within analysis of variance in unadjusted and analysis of covariance in adjusted analysis; B-H – statistically significant secondary outcomes at 10% false discovery rate calculated using Benjamini-Hochberg method; n.s. – not significant at FDR≤10%.
†Means were adjusted for age, sex, education, and employment status.

**TABLE 4.** Correlations of salivary cortisol and tests’ results*

|                      | Before the test | Preparation (3rd min.) | Presentation (8th min.) | Mental arithmetic (13th min.) | 30th min. after the test |
|----------------------|----------------|------------------------|--------------------------|-----------------------------|-------------------------|
|                      | ρ   | p       | ρ   | p       | ρ   | p       | ρ   | p       | ρ   | p       |
| **FEP (n = 53)**     |     |         |     |         |     |         |     |         |     |         |
| IPIP                 |     |         |     |         |     |         |     |         |     |         |
| Extraversion         | -0.06 | 0.697 | -0.09 | 0.540 | -0.05 | 0.709 | -0.01 | 0.943 | 0.07 | 0.618 |
| Agreeableness        | -0.25 | 0.080 | -0.22 | 0.129 | -0.14 | 0.339 | -0.03 | 0.863 | 0.11 | 0.444 |
| Conscientiousness    | 0.28  | 0.046 | 0.15  | 0.310 | 0.03  | 0.839 | 0.10  | 0.481 | 0.18 | 0.217 |
| Emotional stability  | 0.40  | 0.004† | 0.40  | 0.003† | 0.27  | 0.056 | 0.27  | 0.060 | 0.13 | 0.365 |
| Intellect/Imagination| -0.16 | 0.277 | -0.19 | 0.179 | -0.20 | 0.162 | -0.24 | 0.096 | -0.21 | 0.134 |
| SES                  | -0.24 | 0.089 | -0.29 | 0.041 | -0.20 | 0.160 | -0.19 | 0.193 | -0.01 | 0.966 |
| Total PANSS score    | 0.37  | 0.006† | 0.26  | 0.066 | 0.20  | 0.156 | 0.10  | 0.495 | 0.24 | 0.087 |
| PANSS subscales      |     |         |     |         |     |         |     |         |     |         |
| positive symptoms    | 0.36  | 0.008† | 0.24  | 0.091 | 0.19  | 0.169 | 0.08  | 0.590 | 0.20 | 0.158 |
| negative symptoms    | 0.27  | 0.055 | 0.16  | 0.246 | 0.08  | 0.566 | -0.01 | 0.926 | 0.14 | 0.308 |
| general symptoms     | 0.34  | 0.012† | 0.26  | 0.058 | 0.22  | 0.114 | 0.15  | 0.285 | 0.24 | 0.085 |
| **Control group (n = 63)** |     |         |     |         |     |         |     |         |     |         |
| IPIP                 |     |         |     |         |     |         |     |         |     |         |
| Extraversion         | 0.12  | 0.365 | 0.11  | 0.390 | 0.12  | 0.371 | 0.03  | 0.836 | 0.00 | 0.985 |
| Agreeableness        | -0.22 | 0.089 | -0.21 | 0.103 | -0.23 | 0.072 | -0.21 | 0.098 | -0.14 | 0.262 |
| Conscientiousness    | -0.11 | 0.392 | -0.20 | 0.121 | -0.10 | 0.434 | 0.00  | 0.974 | 0.01 | 0.934 |
| Emotional stability  | 0.31  | 0.014† | 0.27  | 0.032 | 0.36  | 0.004† | 0.32  | 0.011† | 0.35 | 0.005† |
| Intellect/Imagination| -0.35 | 0.006† | -0.34 | 0.008† | -0.36 | 0.004† | -0.30 | 0.017† | -0.35 | 0.006† |
| SES                  | -0.33 | 0.008† | -0.35 | 0.005† | -0.32 | 0.010† | -0.21 | 0.092 | -0.28 | 0.024† |

*Abbreviations: ρ – Spearman’s coefficient of rank correlation; p – statistical significance of the correlation coefficient, PANSS – The Positive and Negative Syndrome Scale for Schizophrenia; IPIP – The International Personality Item Pool; SES – Rosenberg Self-Esteem Scale.
†Statistically significant at FDRs 10% using a Benjamini-Hochberg method.
study among patients with FEP, which reported a blunted cortisol response to stressful activities, both on and off medication, compared with controls, although with no differences in baseline salivary cortisol levels (18). Interestingly, these findings are in line with studies among patients with posttraumatic stress disorder, who had increased cortisol levels and a lack of cortisol response during stress (20,21). A similar pattern was observed in healthy individuals with high trait anxiety (22), suggesting that high trait anxiety may be associated with an inability to respond to acute stress stimuli with adequate hormone release. The common feature in these disorders is unresolved early-life trauma, which produces chronic posttraumatic stress disorder, increases the vulnerability to stress, and eventually develops into other psychiatric disorders depending upon a variety of factors. Indeed, psychiatric disorders to a high degree share genetic and environmental roots, and the comorbidity of psychiatric disorders in clinical practice is very high, indicating common pathogenetic mechanisms (35). Thus, the question posed beyond psychotic illness is the effect of lifetime traumatic experiences on blunted neuroendocrine stress response, also observed in a recent publication (17). Since the effects of early trauma and the HPA axis adaptation over time are complex, different alterations of stress responses have been proposed as results of traumatic experiences, including elevated cortisol levels (36), dampened cortisol levels (37), and both increased (38) and blunted (39) stress-induced activation of sensitive brain regions.

However, a study by Seitz et al with a similar design and sample size to our study reported a different main result (17). They found that patients with FEP showed significantly lower cortisol levels throughout the afternoon testing period, but with no difference in the cortisol response to the Trier Social Stress Test compared with controls (17). While these differences may arise from the differences in the samples unrelated to FEP but associated with baseline cortisol, such as smoking or sex, they may also reflect the effect of FEP phase (acute, sub-acute) or medications. This phase-specific effect may be even more evident when it comes to the discrepancies between different studies in baseline salivary cortisol among patients with FEP, as we found higher baseline salivary cortisol levels in patients with more severe psychopathology, especially with positive and general psychotic symptoms. This is compatible with another study, in which the severity of acute psychotic symptoms correlated with the hyperactivity of the HPA axis. Increased cortisol levels can lead to the sensitization of dopaminergic response to stress, which can cause an excessive dopamine release and psychotic symptoms (6), while in turn high dopamine levels produce psychotic experience, creating a vicious cycle.

The administration of antipsychotic treatments, which all act as dopamine receptor antagonists, may also influence cortisol levels. Zhang et al (40) found decreased baseline blood cortisol with the administration of risperidone and haloperidol in patients with schizophrenia, a finding that also correlated with a decrease in negative psychotic symptoms. Although blood baseline cortisol may not be an accurate measure, it is still worth investigating. Another question is whether antipsychotics administration may influence salivary cortisol response to stressors. Antipsychotics, but also other psychotropic drugs, such as antidepressants, alter HPA activity, but the extent and the direction of change is not well understood (11). To our knowledge, there are still no data regarding the influence of antipsychotics on the salivary cortisol response to stressors among patients with FEP. However, it was found that aripiprazole in the water blunts the stress response of exposed fish in a concentration ten times lower than the environmental concentration (41). Nonetheless, it is very difficult to separate the effects of medication and the effects of the illness per se in patients who are in the sub-acute phase.

Interestingly, Vaessen et al (18) found no differences between patients on and off medication, which possibly indicates that psychosis itself can contribute to a blunted stress response. Regardless whether the cause of decreased dopamine in the sub-acute phase is illness-associated or medication-induced (42), dopamine decrease may interfere with the activation of CRF, a major HPA-axis activator in stress response (39). This could possibly contribute to a blunted stress response in patients with psychosis or other psychiatric disorders. Interestingly, decreased general cortisol levels during the psychosocial stress test were associated with less active coping and lower self-esteem in patients with FEP but not in controls (17). Our results were partially concordant, as low cortisol levels were observed with higher self-esteem and high emotional stability, but only in controls. As this result was only exploratory, we will not discuss it further, apart from acknowledging the role of personality dimensions and self-esteem as possible mediators of cortisol response to psychosocial stressors unrelated to psychosis.

The strengths of this study are a relatively large sample of patients with FEP, homogenous in terms of age, diagnosis, and of phase of illness. However, the study also has
several limitations. First, as we chose a consecutive sample of patients with FEP and a convenient control sample, the study may suffer from sample bias and limited representativeness of the targeted populations. Second, we cannot guarantee that the participants adhered to the protocol for saliva collection in terms of drink, food, and tobacco consumption although we relied on participants’ self-reports. Other factors (eg, cannabis use) may affect the levels of salivary cortisol (43). Although we excluded individuals with addictions to psychoactive substances, these data were obtained by anamnesis only, without the confirmation using urine/ blood screening tests. Thus, we cannot exclude the unreported (occasional) use of cannabis among study participants, given the relatively high percentage of persons with FEP or controls who occasionally use marijuana.

While many alterations in the patients with FEP could be linked to alterations in stress response, a relatively small number of studies focused specifically on psychosocial stress in FEP. Our study supported the hypothesis that patients with FEP showed higher baseline levels of salivary cortisol, and an attenuated stress response to psychosocial stressor compared with healthy controls, suggesting that their vulnerability to stress arises from the decreased adaptive ability of cortisol to increase in response to stressors. Although these results are interesting and it seems reasonable that stress-coping strategies should be included in patients’ treatment plan, it is yet unclear whether these findings result from the specific effects of psychosis or other factors, including medication. Thus, we plan to follow-up these patients over a long period and analyze the influence of the mentioned factors.

References

1. Kuzman Rojnic M, Makaric P, Bosnjak Kuharic D, Kekin I, Rossini Gajšak L, Boban M, et al. Integration of complementary biomarkers in patients with first episode psychosis: research protocol of a prospective follow up study. Psychiatr Danub. 2019;31:162-71. doi:10.24869/psyd.2019.162
2. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635-45. Medline:19700006 doi:10.1016/S0140-6736(09)60995-8
3. Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997;104:667-85. Medline:9337628 doi:10.1037/0033-295X.104.4.667
4. Maynard TM, Sikich L, Lieberman JA, LaManita AS. Neural development, cell-cell signaling, and the “two-hit” hypothesis of schizophrenia. Schizophr Bull. 2001;27:457-76. Medline:11596847 doi:10.1093/oxfordjournals.schbul.a006887
5. Isuru A, Hewage SN, Bandumithra P, Williams SS. Unconfirmed death as a predictor of psychological morbidity in family members of disappeared persons. Psychol Med. 2018;•••:1-8. Medline:30585557
6. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry. 2012;71:561-7. Medline:22133268 doi:10.1016/j.biopsych.2011.10.009
7. Hellhammer DH, Wüst S, Kudielka BM. Salivary cortisol as a biomarker in stress research. Psychoneuroendocrinology. 2009;34:163-71. Medline:19095358 doi:10.1016/j.psyneuen.2008.10.026
8. Gajšak LR, Gelemanovic A, Kuzman MR, Puljak L. Impact of stress response in development of first-episode psychosis in schizophrenia: An overview of systematic reviews. Psychiatr Danub. 2017;29:14-23. Medline:28291969 doi:10.24869/psyd.2017.14
9. Labad J. The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders. Psychoneuroendocrinology. 2019;102:24-36. Medline:30503781 doi:10.1016/j.psyneuen.2018.11.028
10. Dauvermann MR, Donohoe G. Cortisol stress response in psychosis from the high-risk to the chronic stage: a systematic review. Ir J Psychol Med. 2019;36:305-15. Medline:31317845 doi:10.1017/ipm.2019.27
11. Walker E, Mittal V, Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol. 2008;4:189-216. Medline:18370616 doi:10.1146/annurev.clinpsy.4.022007.141248
12. Coulon N, Brailly-Tabard S, Walter M, Tordjman S. Altered circadian patterns of salivary cortisol in individuals with schizophrenia: A critical literature review. J Physiol Paris. 2016;110:4 Pt B:439-47. Medline:28506881 doi:10.1016/j.jphysparis.2017.05.002
13. Pruessner M, Bechard-Evans L, Pira S, Joober R, Collins DL, Pruessner JC, et al. Interplay of hippocampal volume and...
hypothalamus-pituitary-adrenal axis function as markers of stress vulnerability in men at ultra-high risk for psychosis. 

Psychol Med. 2017;47:471-83. Medline:27774914 doi:10.1017/S0033291716002658

14 Chaumette B, Kebrir O, Mam-Lam-Fook C, Morvan Y, Bourgin J, Godsil BP, et al. Salivary cortisol in early psychosis: New findings and meta-analysis. Psychoneuroendocrinology. 2016;63:262-70. Medline:26520686 doi:10.1016/j.psyneuen.2015.10.007

15 van Venrooij JAEM, Fluitman SBHA, Lijmert JC, Kavelaars A, Heijnen CJ, Westenberg HGM, et al. Impaired neuroendocrine and immune response to acute stress in medication-naïve patients with a first episode of psychosis. Schizophr Bull. 2012;38:272-9. Medline:20558533 doi:10.1093/schbul/sbo062

16 Puessner M, Béchard-Évans L, Boekestyn L, Iyer SN, Puessner JC, Malla AK. Attenuated cortisol response to acute psychosocial stress in individuals at ultra-high risk for psychosis. Schizophr Res. 2013;146:79-86. Medline:23510595 doi:10.1016/j.schres.2013.02.019

17 Seitz R, Vractas N, Bechard-Évans L, King S, Abadi S, Joober R, et al. The Trier Social Stress Test in first episode psychosis patients: Impact of perceived stress, protective factors and childhood trauma. Psychoneuroendocrinology. 2019. Medline:30658856 doi:10.1016/j.psyneuen.2019.06.007

18 Vaessen T, Kasanova Z, Hernaust D, Lataster J, Collip D, van Nierop M, et al. Overall cortisol, diurnal slope, and stress reactivity in psychosis: An experience sampling approach. Psychoneuroendocrinology. 2018. Medline:29906787 doi:10.1016/j.psyneuen.2018.06.007

19 Ciufolini S, Dazzan P, Kempton MJ, Pariante C, Mondelli V. HPA axis response to social stress is attenuated in schizophrenia but normal in depression: Evidence from a meta-analysis of existing studies. Neurosci Biobehav Rev. 2014. Medline:25246294 doi:10.1016/j.neubiorev.2014.09.004

20 Bremner JD, Vythilingam M, Vermetten E, Khan S, Nazeer JC, et al. Cortisol response to a cognitive stress challenge in posttraumatic stress disorder (PTSD) related to childhood abuse. Psychoneuroendocrinology. 2003;28:733-50. Medline:12812861 doi:10.1016/S0306-4530(02)00067-7

21 Kolassa I-T, Eckart C, Ruf M, Neuner F, de Quervain DJ, Elbert T. Lack of cortisol response in patients with posttraumatic stress disorder (PTSD) undergoing a diagnostic interview. BMC Psychiatry. 2007;7:54. Medline:17916253 doi:10.1186/1471-244X-7-54

22 Jezova D, Makatsori A, Duncko R, Moncek F, Jakubek M. High trait anxiety in healthy subjects is associated with low neuroendocrine activity during psychosocial stress. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1331-6. Medline:15588760 doi:10.1016/j.pnpbp.2004.08.005

23 World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-4. Medline:24141714 doi:10.1001/jama.2013.281053

24 World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Vol. 41, Occupational Health. 1992. 1–201 p.

25 Rosenberg M. Society and the adolescent self-image. Princeton, NJ: University Press. 1965.

26 Goldberg LR, Johnson JA, Eber HW, Hogan R, Ashton MC, Cloninger CR, et al. The international personality item pool and the future of public-domain personality measures. J Res Pers. 2006. doi:10.1016/j.jrper.2005.08.007

27 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-76. Medline:3616518 doi:10.1093/schbul/13.2.261

28 Dedovic K, Renwick R, Mahani NK, Engert V, Lupien SJ, Puessner JC. The Montreal Imaging Stress Task: using functional imaging to investigate the effects of perceiving and processing psychosocial stress in the human brain. J Psychiatry Neurosci. 2005;30:319-25. Medline:16151536

29 Kirschbaum C, Pirke KM, Hellhammer DH. The ‘Trier Social Stress Test’–a tool for investigating psychobiological stress responses in a laboratory setting, Neuropsychobiology. 1993;28:76-81. Medline:8255414 doi:10.1159/000119004

30 Dressendorfer RA, Kirschbaum C, Rohde W, Stahl F, Strasburger CJ. Synthesis of a cortisol-biotin conjugate and evaluation as a tracer in an immunoassay for salivary cortisol measurement. J Steroid Biochem Mol Biol. 1992;43:683-92. Medline:1472460 doi:10.1016/0960-7667(92)90294-S

31 Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull. 2004;130:355-91. Medline:15122924 doi:10.1037/0033-2909.130.3.355

32 Chiu SK, Collier CP, Clark AF, Wynn-Edwards KE. Salivary cortisol on ROCHE Elecsys immunoassay system: pilot biological variation studies. Clin Biochem. 2003;36:211-4. Medline:12726930 doi:10.1016/S0009-9236(02)00471-X

33 Hanrahan K, McCarthy AM, Kleiber C, Lutgendorf S, Talikian E. Strategies for salivary cortisol collection and analysis in research with children. Appl Nurs Res. 2006;19:95-101. Medline:16728293 doi:10.1016/j.apnr.2006.02.001

34 R Foundation for Statistical Computing. Vienna, Austria. Available from: www.R-project.org. Accessed: February 21, 2021.

35 Wang K, Gaitsch H, Poon H, Cox NJ, Rhetsky A. Classification of common human diseases derived from shared genetic and environmental determinants. Nat Genet. 2017;49:1319-25. Medline:2878316 doi:10.1016/j.pnbp.2019.04.005

36 Heim C, Mletzko T, Purselle D, Musselman DL, Nemeroff CB. Immune response to acute stress in medication-naive patients with major depression: role of childhood trauma. Biol Psychiatry. 2004;56:406-13. Medline:15588760 doi:10.1016/j.bcp.2014.08.001
37 Roy A. Urinary free cortisol and childhood trauma in cocaine dependent adults. J Psychiatr Res. 2007;41:173-7. Medline:11866695 doi:10.1016/S0022-3956(07)00002-X

38 Grant MM, Cannistraci C, Hollon SD, Gore J, Shelton R. Childhood trauma history differentiates amygdala response to sad faces within MDD. J Psychiatr Res. 2011;45:886-95. Medline:21276593 doi:10.1016/j.jpsychires.2010.12.004

39 Kim S, Fonagy P, Allen J, Strathearn L. Mothers’ unresolved trauma blunts amygdala response to infant distress. Soc Neurosci. 2014;9:352-63. Medline:24635646 doi:10.1080/17470919.2014.896287

40 Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology. 2005;30:1532-8. Medline:15886721 doi:10.1038/sj.npp.1300756

41 Barcellos HH de A, Kalichak F, da Rosa JGS, Oliveira TA, Koakoski G, Idalencio R, et al. Waterborne aripiprazole blunts the stress response in zebrafish. Sci Rep. 2016;6:37612. Medline:27874070 doi:10.1038/srep37612

42 Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8:303-18. Medline:30344997 doi:10.1177/2045125318781475

43 King GR, Ernst T, Deng W, Stenger A, Gonzales RMK, Nakama H, et al. Altered brain activation during visuomotor integration in chronic active cannabis users: relationship to cortisol levels. J Neurosci. 2011;31:17923-31. Medline:22159107 doi:10.1523/JNEUROSCI.4148-11.2011